Past BTD application -- WOW !! All patients in
Post# of 154064
(Total Views: 639)
Posted On: 06/10/2025 12:17:21 AM
Past BTD application -- WOW !!
All patients in the study received ≥1 doses of leronlimab (range 1-51) by subcutaneous infusion in conjunction with SOC systemic chemotherapy.
Nine out of 28 patients received leronlimab dosed at 350mg weekly dose
and 19 subjects received the 525-mg or 700-mg weekly dose.
Notably, 4 subjects had dose escalation from 350-mg dose level to the 525-mg dose level.
The population had a median age of 52 years (range, 33-84 years).
Patients were diagnosed with stage IV mTNBC,
and 61% of subjects started with visceral metastases,
21 patients had brain metastases,
and 11% had bone-only metastases.
___
The BTD application news release Nov 8, 2021.
BTD applications do not have an expiration date.
Brain & bone data dominant @ 72% of the patient population.
Now look @ the ESMO poster.
Totally different data releases between the two.
BTD & ESMO data is from the same 3 trials:
*NCT0383867 -- 30 @ 350mg dose escalation
*NCT04313075 -- 30 with Carboplatin
*NCT04504942 -- 30 @ Basket Trial
BTD & ESMO = 60 of 90 patients
(that BTD is stunning @ 21 brain mets)
What else is in that Amarex data dump ??
There is still 30 more patients with data !!
All patients in the study received ≥1 doses of leronlimab (range 1-51) by subcutaneous infusion in conjunction with SOC systemic chemotherapy.
Nine out of 28 patients received leronlimab dosed at 350mg weekly dose
and 19 subjects received the 525-mg or 700-mg weekly dose.
Notably, 4 subjects had dose escalation from 350-mg dose level to the 525-mg dose level.
The population had a median age of 52 years (range, 33-84 years).
Patients were diagnosed with stage IV mTNBC,
and 61% of subjects started with visceral metastases,
21 patients had brain metastases,
and 11% had bone-only metastases.
___
The BTD application news release Nov 8, 2021.
BTD applications do not have an expiration date.
Brain & bone data dominant @ 72% of the patient population.
Now look @ the ESMO poster.
Totally different data releases between the two.
BTD & ESMO data is from the same 3 trials:
*NCT0383867 -- 30 @ 350mg dose escalation
*NCT04313075 -- 30 with Carboplatin
*NCT04504942 -- 30 @ Basket Trial
BTD & ESMO = 60 of 90 patients
(that BTD is stunning @ 21 brain mets)
What else is in that Amarex data dump ??
There is still 30 more patients with data !!
(4)
(0)